CymaBay Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBAY research report →
Companywww.cymabay.com
CymaBay Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.
- CEO
- Sujal A. Shah
- IPO
- 2014
- Employees
- 101
- HQ
- Newark, CA, US
Price Chart
Valuation
- Market Cap
- $3.73B
- P/E
- -32.74
- P/S
- 119.98
- P/B
- 11.80
- EV/EBITDA
- -42.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.81%
- Op Margin
- -327.23%
- Net Margin
- -339.10%
- ROE
- -64.17%
- ROIC
- -24.93%
Growth & Income
- Revenue
- $31.07M · 0.00%
- Net Income
- $-105,370,000 · 11.37%
- EPS
- $-0.99 · 26.67%
- Op Income
- $-101,679,000
- FCF YoY
- 13.36%
Performance & Tape
- 52W High
- $32.50
- 52W Low
- $7.26
- 50D MA
- $28.59
- 200D MA
- $18.42
- Beta
- 0.32
- Avg Volume
- 3.94M
Get TickerSpark's AI analysis on CBAY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 22, 24 | Loewy Caroline M | sell | 32,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 30,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 15,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 7,500 |
| Mar 22, 24 | Loewy Caroline M | sell | 16,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 27,705 |
| Mar 22, 24 | Loewy Caroline M | sell | 49,245 |
| Mar 22, 24 | Loewy Caroline M | sell | 67,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 25,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 14,010 |
Our CBAY Coverage
We haven't published any research on CBAY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CBAY Report →